Song, LouJin
Bekdash, Ramsey http://orcid.org/0000-0003-1825-7130
Morikawa, Kumi
Quejada, Jose R.
Klein, Alison D.
Aina-Badejo, Danielle
Yoshida, Kazushige
Yamamoto, Hannah E.
Chalan, Amy
Yang, Risako
Patel, Achchhe
Sirabella, Dario
Lee, Teresa M.
Joseph, Leroy C.
Kawano, Fuun
Warren, Junco S.
Soni, Rajesh K.
Morrow, John P.
Yazawa, Masayuki http://orcid.org/0000-0002-5730-6583
Funding for this research was provided by:
Columbia University (TRANSFROM TL1 Training program, TRANSFROM TL1 Training program, Core Usage Funding Program)
MEXT | Japan Society for the Promotion of Science (JSPS Postdoc fellowship)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (F31HL142239, R01HL136758, K99/R00HL111345, R01HL138486)
Leona M. and Harry B. Helmsley Charitable Trust (Helmsley Stem Cell Seed Grant)
Article History
Received: 27 October 2021
Accepted: 22 December 2021
First Online: 17 February 2022
Competing interests
: L.S., R.B., K.M., J.R.Q. and M.Y. (inventors) filed a patent (attorney docket no. 01001/005273-US1; status, filed, 4 October 2019) related to this manuscript. This patent is for using SIGMAR1 agonists to treat LQTS (types 1, 2 and 8) and related cardiac channelopathy. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.